{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+B%3A+placebo&page=6", "query": { "intervention": "Cohort B: placebo", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 422, "total_pages": 43, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+B%3A+placebo&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+B%3A+placebo&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T09:11:49.162Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01423318", "title": "A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "lebrikizumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 60, "start_date": "2011-08", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-03T09:11:49.162Z", "location_count": 1, "location_summary": "Honolulu, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01423318" }, { "nct_id": "NCT07662148", "title": "A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "BIIB144", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2026-07-21", "completion_date": "2028-06-19", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-03T09:11:49.162Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT07662148" }, { "nct_id": "NCT01621243", "title": "M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Necuparanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Momenta Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 128, "start_date": "2012-05", "completion_date": "2016-10-24", "has_results": false, "last_update_posted_date": "2018-08-29", "last_synced_at": "2026-10-03T09:11:49.162Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01621243" }, { "nct_id": "NCT06177691", "title": "Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Type1 Diabetes" ], "interventions": [], "intervention_types": [], "sponsor": "Jaeb Center for Health Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "7 Years to 17 Years" }, "enrollment_count": 77, "start_date": "2021-05-07", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-03T09:11:49.162Z", "location_count": 6, "location_summary": "Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06177691" }, { "nct_id": "NCT00281008", "title": "Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercholesterolemia, Familial" ], "interventions": [ { "name": "ISIS 301012 or Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kastle Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2006-02", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2016-08-03", "last_synced_at": "2026-10-03T09:11:49.162Z", "location_count": 7, "location_summary": "Chicago, Illinois • Auburn, Maine • Scarborough, Maine + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Auburn", "state": "Maine" }, { "city": "Scarborough", "state": "Maine" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00281008" }, { "nct_id": "NCT05747924", "title": "Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "FSHD", "FSHD1", "FSHD2", "FMD", "FMD2", "Fascioscapulohumeral Muscular Dystrophy", "Fascioscapulohumeral Muscular Dystrophy Type 1", "Fascioscapulohumeral Muscular Dystrophy Type 2", "Dystrophies, Facioscapulohumeral Muscular", "Dystrophy, Facioscapulohumeral Muscular", "Facioscapulohumeral Muscular Dystrophy 1", "Facioscapulohumeral Muscular Dystrophy 2", "Facio-Scapulo-Humeral Dystrophy", "Atrophy, Facioscapulohumeral", "Atrophies, Facioscapulohumeral", "Facioscapulohumeral Atrophy", "Muscular Dystrophies", "Muscular Dystrophy, Facioscapulohumeral", "FSH Muscular Dystrophy", "Landouzy Dejerine Dystrophy", "Landouzy-Dejerine Muscular Dystrophy", "Dystrophies, Landouzy-Dejerine", "Dystrophy, Landouzy-Dejerine", "Landouzy-Dejerine Syndrome", "Muscular Dystrophy, Landouzy Dejerine", "Progressive Muscular Dystrophy", "FSH" ], "interventions": [ { "name": "AOC 1020", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 90, "start_date": "2023-04-04", "completion_date": "2026-03-20", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-03T09:11:49.162Z", "location_count": 14, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05747924" }, { "nct_id": "NCT00697710", "title": "A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "50 mg S-777469", "type": "DRUG" }, { "name": "200 mg S-777469", "type": "DRUG" }, { "name": "800 mg S-777469", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shionogi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2007-07", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2018-05-01", "last_synced_at": "2026-10-03T09:11:49.162Z", "location_count": 1, "location_summary": "Miramar, Florida", "locations": [ { "city": "Miramar", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00697710" }, { "nct_id": "NCT04649541", "title": "Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Safety" ], "interventions": [ { "name": "MRX-8", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MicuRx", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 69, "start_date": "2020-11-29", "completion_date": "2021-12-01", "has_results": false, "last_update_posted_date": "2023-08-24", "last_synced_at": "2026-10-03T09:11:49.162Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04649541" }, { "nct_id": "NCT07159841", "title": "A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Congenital Adrenal Hyperplasia", "Classic Congenital Adrenal Hyperplasia" ], "interventions": [ { "name": "Atumelnant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crinetics Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 153, "start_date": "2026-01-22", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-03T09:11:49.162Z", "location_count": 10, "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07159841" }, { "nct_id": "NCT04629105", "title": "Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ARDS, Human", "Covid19" ], "interventions": [ { "name": "Longeveron Mesenchymal Stem Cells (LMSCs)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Longeveron Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2020-07-24", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-10-03T09:11:49.162Z", "location_count": 3, "location_summary": "Miami, Florida • Baltimore, Maryland • Winston-Salem, North Carolina", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629105" } ] }